Pavmed Stock Price, News & Analysis

Lucid Diagnostics reported Q3 2024 financial results with EsoGuard® revenue of $1.2M, showing a 20% sequential increase from Q2 and 50% annual growth. The company performed 2,787 commercial EsoGuard tests in Q3, with October setting a single-month record of over 1,400 tests. Operating expenses were $12.9M, resulting in a GAAP net loss of $12.4M or $(0.25) per share. Cash position stood at $14.5M as of September 30, 2024. The company has secured agreements for $21.75M in Senior Secured Convertible Notes and expects to increase its cash runway by approximately $13.2M after redemption of existing notes.

Lucid Diagnostics (NASDAQ: LUCD) announced the acceptance of its ESOGUARD BE-1 study manuscript for publication in The American Journal of Gastroenterology. The study, led by Dr. Nicholas J. Shaheen, validates the EsoGuard® Esophageal DNA Test performance in detecting esophageal precancer. The test demonstrated approximately 88% sensitivity and 99% negative predictive value, with 81% specificity and 30% positive predictive value. This fourth clinical validation publication completes Lucid's evidence package for Medicare coverage submission. The multicenter study was conducted across leading U.S. and European medical centers, showing strong performance in screening populations with no serious adverse events reported.

Lucid Diagnostics (LUCD) announces expansion of its direct contracting initiative to drive near-term revenue for its EsoGuard® Esophageal DNA Test. The company is focusing on three main programs: fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. To support these initiatives, Lucid has hired two experienced professionals from GRAIL, Inc. The company recently completed its first major directly-contracted testing event with Fort Worth Fire Department, where 200 firefighters received EsoGuard testing. The expansion targets self-insured entities, concierge medicine practices, and employer-funded health plans through strategic partnerships and broker networks.

PAVmed (Nasdaq: PAVM, PAVMZ), a commercial-stage medical technology company, has announced a business update conference call and webcast scheduled for November 14, 2024, at 8:30 AM ET. During the call, Chairman and CEO Lishan Aklog, M.D., will discuss company operations and growth strategy, while President and CFO Dennis McGrath will present third quarter 2024 financial results.

U.S. callers can join via 1-800-836-8184, while international participants should dial 1-646-357-8785. The webcast will be accessible through the company's investor relations website at pavmed.com, with a 30-day replay available afterward.

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and PAVmed subsidiary, announces a business update conference call and webcast scheduled for November 13, 2024, at 8:30 AM ET. Chairman and CEO Lishan Aklog will provide operational updates and growth strategy insights, while CFO Dennis McGrath will present Q3 2024 financial results.

The webcast will be accessible through the company's investor relations website at luciddx.com. U.S. callers can dial 1-800-836-8184, and international callers 1-646-357-8785, referencing 'Lucid Diagnostics Business Update' to join. A 30-day replay will be available on the company website afterward.

Lucid Diagnostics Inc. (Nasdaq: LUCD) has received a Notice of Allowance from the USPTO for a patent application covering its proprietary method of using methylation of the cyclin-A1 (CCNA1) gene to detect esophageal precancer and cancer. This patent strengthens Lucid's intellectual property portfolio and protects a key component of its EsoGuard® Esophageal DNA Test.

EsoGuard uses next-generation sequencing to assess DNA methylation at 31 sites on two genes, vimentin (VIM) and CCNA1. The association of CCNA1 methylation with esophageal neoplasia is novel and appears to be more specific than VIM methylation. The technology behind EsoGuard and the EsoCheck® Esophageal Cell Collection Device was developed at Case Western Reserve University, with Lucid holding the exclusive worldwide license to commercialize it.

PAVmed's subsidiary, Veris Health, has been awarded a $1.8 million grant from the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH). The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center.

The research project, titled 'Bridging the Gap: Enhancing Cancer Care for Underserved Populations with the Veris Health Cancer Care Platform,' will focus on patients facing language barriers, access to technology, and socioeconomic disparities. This non-dilutive funding comes at a important time for Veris as it pursues financing to advance its commercial strategy, including regulatory clearance and launch of its implantable physiological monitor.

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event will feature a fireside chat with Dennis McGrath, Lucid's Chief Financial Officer, scheduled for Tuesday, October 15, 2024, at 11:30 AM Eastern Time.

Interested parties can attend the virtual fireside chat by visiting the provided link. Following the conference, a recording of the session will be available on Lucid's investor relations website. This participation demonstrates Lucid's commitment to engaging with investors and sharing insights about their cancer prevention diagnostics business.

Lucid Diagnostics (Nasdaq: LUCD) announced its participation in The MedTech Conference 2024, scheduled for October 15-17 in Toronto, Canada. The company will showcase its EsoGuard® and EsoCheck® technologies in the conference's Innovation Pavilion, offering live demonstrations to attendees. Lishan Aklog, M.D., Lucid's Chairman and CEO, will participate in a CEOs Unplugged event alongside industry leaders. Additionally, Shaun O'Neil, Lucid's President and COO, will deliver the company's presentation at the conference's Investor Forum.

Lucid's presence at the conference, organized by AdvaMed, provides an opportunity to engage with industry leaders, potential partners, and investors. The event is expected to attract over 1,500 companies and attendees from 45 countries, highlighting its significance in the medical technology industry.